In this installment of the “How I treat ...” series in Blood, the authors outline the somatic or germline mutations that are the underlying cause of juvenile myelomonocytic leukemia (JMML) and describe their treatment algorithm for this aggressive hematopoietic disorder of infancy/early childhood. They note that allogeneic HCT “remains the therapy of choice for most patients with JMML, curing more than 50% of affected children” and they recommend that this option be promptly offered to any child with PTPN-11-, K-RAS-, or NF1-mutated JMML and to the majority of those with N-RAS mutations. They also discuss the recent use of the hypomethylating agent azacytidine in treating JMML, and its ability to induce hematologic/molecular remissions in some children with the disorder and possible use in reducing leukemia burden prior to HCT.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Review: How I Treat JMML
Feb 2015